Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05799157 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts
A Phase 2 study, sponsored by Veradermics.
- Completed
- Registry status
- Phase 2
- Development phase
- 153
- Enrollment target
NCT05799157 is a Phase 2 study that has completed, run by Veradermics. The registered enrollment target is 153 participants.
The verdict
NCT05799157, a Phase 2 study, has completed, sponsored by Veradermics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 153 participants
- Enrollment target
Study Summary
This Phase 2 study has been designed to determine the safety and efficacy of repeated treatment sessions of VDMN-21 patch at two dose strengths as compared to a matched vehicle control patch in subjects with verruca vulgaris
Interventions
- DRUG VDMN-21 Patch Low Dose
- DRUG VDMN-21 Patch High Dose
- DRUG Vehicle Patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2023-02-28 |
| Est. Completion | 2025-02-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05799157
The ClinicalTrials.gov registry entry for NCT05799157 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 153 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Veradermics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which VDMN-21 Patch Low Dose is the first listed.
NCT05799157 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05799157 about?
NCT05799157 is a clinical study titled "Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts". This Phase 2 study has been designed to determine the safety and efficacy of repeated treatment sessions of VDMN-21 patch at two dose strengths as compared to a matched vehicle control patch in subjects with verruca vulgaris
What is the current status of trial NCT05799157?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 153 participants. The study started on 2023-02-28. Estimated completion is 2025-02-25.
What interventions are being tested in trial NCT05799157?
The interventions under investigation include: VDMN-21 Patch Low Dose (DRUG), VDMN-21 Patch High Dose (DRUG), Vehicle Patch (DRUG).
Who is sponsoring clinical trial NCT05799157?
This trial is sponsored by Veradermics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.